Nanomedicine platform for targeting activated neutrophils and neutrophil-platelet complexes using an α1-antitrypsin-derived peptide motif.
Nat Nanotechnol
; 17(9): 1004-1014, 2022 09.
Article
em En
| MEDLINE
| ID: mdl-35851383
ABSTRACT
Targeted drug delivery to disease-associated activated neutrophils can provide novel therapeutic opportunities while avoiding systemic effects on immune functions. We created a nanomedicine platform that uniquely utilizes an α1-antitrypsin-derived peptide to confer binding specificity to neutrophil elastase on activated neutrophils. Surface decoration with this peptide enabled specific anchorage of nanoparticles to activated neutrophils and platelet-neutrophil aggregates, in vitro and in vivo. Nanoparticle delivery of a model drug, hydroxychloroquine, demonstrated significant reduction of neutrophil activities in vitro and a therapeutic effect on murine venous thrombosis in vivo. This innovative approach of cell-specific and activation-state-specific targeting can be applied to several neutrophil-driven pathologies.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Elastase de Leucócito
/
Deficiência de alfa 1-Antitripsina
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Nat Nanotechnol
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos